Discussions With Your Doctor

What to ask about ZYNLONTA® (loncastuximab tesirine-lpyl)

Discussions With Your Doctor

What to ask about ZYNLONTA® (loncastuximab tesirine-lpyl)

Not an actual patient.

How to discuss what’s next after 2 or more diffuse large B-cell lymphoma (DLBCL) therapies

Diffuse Large B-Cell Lymphoma (DLBCL) — A type of B-cell non-Hodgkin lymphoma (cancer of the immune system) that is usually aggressive (fast-growing). It is the most common type of non-Hodgkin lymphoma, and is marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs.

 

Your doctor may explain your options with complicated medical terms. They may use words you’re hearing for the first time or talk about ideas that may be difficult to understand in the moment.

If you have already tried 2 or more past therapies for relapsed/refractory (R/R) DLBCL, but need your next one, a lot of questions may be coming up. If therapies have not worked or are no longer working, it may be difficult to believe a new therapy will. If the cancer continued to grow after past therapies worked, you may also feel let down.

At this time, discussions with your doctor about your options are crucial.

If other therapies have worked, but the cancer returned,
or no other therapies have worked—there’s still hope that another option might help

If you’re considering, or are on ZYNLONTA® therapy, the questions below can help guide future conversations with your doctor.

Take notes and ask as many questions as you need. This way, you can understand more about your therapy.

Ask about whether ZYNLONTA® is right for you

Why you should ask: ZYNLONTA® may not be right for everyone. Ask your doctor if ZYNLONTA® could be the next step for your specific type of R/R DLBCL.

Your doctor will consider a number of factors about your personal health.

ZYNLONTA® may be an option after most DLBCL therapies.
Some adults treated with ZYNLONTA® were able to go on to other therapies

Ask about relapsed vs refractory DLBCL

Something your doctor will take into account is whether the cancer has relapsed or is refractory. Use the flow chart below to figure out where your cancer falls.

Why you should ask: There are 2 ways to think about how DLBCL has reacted to past therapy. Use the flow chart below to understand more about what your doctor will want to know.

Relapsed vs refractory DLBCL infographicRelapsed vs refractory DLBCL infographic

Ask about therapy information

Why you should ask: Sometimes talking points may not readily come to mind. But these questions are made to open up the conversation with your doctor about ZYNLONTA®. Feel free to download them.

  • What kind of infusion is ZYNLONTA®?
  • Is ZYNLONTA® right for my specific condition?
  • How well does ZYNLONTA® work?
  • How is ZYNLONTA® given?
  • How long does each treatment take? How often is ZYNLONTA® given?
  • When can I start seeing results with ZYNLONTA®? How will I know it’s working?
  • Before taking ZYNLONTA®: Will I need to take any medications? Do I need to do anything else?
  • How often will blood tests be done?
  • Does it matter what therapy I was on before?
  • Is the therapy different if I have relapsed?
  • Would my therapy be different if the cancer had never responded to therapy before?
  • What are possible side effects I should look out for?
  • What are more serious side effects and which are more common?
  • When should I contact your office about side effects?
  • Is there anything I should avoid taking or doing while on ZYNLONTA®?
  • What are some trusted sources that can help me understand my condition?
  • What are the best ways to reach you when I have questions?
  • How long will I be on ZYNLONTA®?

Track your past therapies so you can answer:

Could ZYNLONTA® (loncastuximab tesirine-lpyl) be my next therapy?

What line of therapy am I at?

If you have been diagnosed with DLBCL and have tried 2 or more therapies, ZYNLONTA® may be right for you. Answer these questions about your treatment history and talk with your doctor about what’s next in your DLBCL treatment plan.

ZYNLONTA® may be an option after most DLBCL therapies. Some adults treated with ZYNLONTA® were able to go on to other therapies afterward.

Please see Important Safety Information below and Full Prescribing Information.

ZYNLONTA® is for people with R/R DLBCL who have tried 2 or more therapies.
Please talk to your doctor about the next steps in your treatment plan.

1. For my 1st DLBCL therapy, I tried __________.

2. After the 1st treatment did not work or the cancer came back, I received my 2nd treatment.

I got a transplant (ASCT) along with:

I couldn’t have an ASCT but instead had:

Neither:

3. My 3rd or later therapy was ______________. (select all that apply)

None:

4. After the latest therapy, the cancer came back (relapsed) or the treatment didn’t work (refractory).

    ADC Therapeutics respects your privacy and personal information. Please read our Privacy Policy for more information. By interacting with the treatment plan content, you are confirming that you have read, understand, and agree with the Privacy Policy for the information collected on the form above.
    Feel free to download your results and share them with your care team.

    All other trademarks, registered or unregistered, are the property of their respective owners

    ASCT: Autologous stem cell transplant

    Anti-CD19: against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities

    CD30+: protein found on some T-cells and B-cells (2 types of white blood cells). It is a receptor for a protein called tumor necrosis factor

    mAb: monoclonal antibody

    Non-GCB: non-germinal center B-cell-type

    HDT: High-dose therapy

    R-DHAP: Rituximab-dexamethasone-high dose cytarabine (Ara C)-cisplatin (platinum)

    R-ESHAP: Rituximab-etoposide-solu-medrone (methylprednisolone)-high dose cytarabine (Ara C)-cisplatin (platinum)

    R-GemOx: Rituximab-Gemcitabine-Oxaliplatin

    R-GDP: Rituximab-Gemcitabine-Dexamethasone-cisPlatin (carboPlatin)

    R-ICE: Rituximab-ifosfamide-carboplatin-etoposide

    Learn about ZYNLONTA®
    results

    Study results icon
    Find results for ZYNLONTA®

    You could save
    on ZYNLONTA® treatment

    ZYNLONTA® support icon
    Learn about financial support
    Expand

    What is ZYNLONTA®?

    ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

    It is not known if ZYNLONTA® is safe and effective in children.

    The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

    IMPORTANT SAFETY INFORMATION

    What are the possible side effects of ZYNLONTA®?

    ZYNLONTA® may cause serious side effects, including:

    • Fluid retention. Your body may hold too much fluid during treatment with ZYNLONTA®. This can be serious. Tell your healthcare provider if you develop new or worsening swelling or puffiness, weight gain, chest pain, shortness of breath, or trouble breathing
    • Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with ZYNLONTA® but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with ZYNLONTA®. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding
    • Read full Important Safety Information
    • Infections. Serious infections, including infections that can cause death, have happened in people treated with ZYNLONTA®. Tell your healthcare provider right away if you have new or worsening signs or symptoms of infection
    • Skin reactions. Serious skin reactions have happened in people treated with ZYNLONTA®. Tell your healthcare provider if you get new or worsening skin reactions, including sensitivity to sunlight, skin rash, peeling, redness or irritation. You may burn more easily or get severe sunburns

    The most common side effects of ZYNLONTA® include:

    • feeling tired or weak
    • skin rash
    • swelling
    • nausea
    • muscle or joint pain
    • increase in blood sugar (hyperglycemia)
    • changes in certain blood or laboratory tests

    ZYNLONTA® may cause fertility problems in males which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ZYNLONTA®.

    What should I avoid while receiving ZYNLONTA®?

    Avoid or limit your exposure to sunlight, including sunlight through glass, such as buildings or vehicle windows and artificial sunlight such as sunlamps or tanning beds. Exposure to sunlight during treatment with ZYNLONTA® can cause skin reaction or rash. Use sun protection measures such as sunscreen and wear loose-fitting clothes that cover your skin while out in sunlight.

    Before you receive ZYNLONTA®, tell your healthcare provider about all of your medical conditions, including if you:

    • have an active infection or have had one recently
    • have liver problems
    • are pregnant or plan to become pregnant. ZYNLONTA® can harm your unborn baby

      Females who can become pregnant:

      • your healthcare provider may do a pregnancy test before starting treatment with ZYNLONTA®
      • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 10 months after the last dose of ZYNLONTA®. Talk to your healthcare provider about effective birth control. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZYNLONTA®

      Males with female partners who can become pregnant:

      • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 7 months after the last dose of ZYNLONTA®
    • are breastfeeding or plan to breastfeed. It is not known if ZYNLONTA® passes into breast milk. Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®

    Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine.

    You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.

    Please see the full Prescribing Information for ZYNLONTA®, including Patient Information, for additional Important Safety Information.

    What is ZYNLONTA®?

    ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

    It is not known if ZYNLONTA® is safe and effective in children.

    The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

    IMPORTANT SAFETY INFORMATION

    What are the possible side effects of ZYNLONTA®?

    ZYNLONTA® may cause serious side effects, including:

    • Fluid retention. Your body may hold too much fluid during treatment with ZYNLONTA®. This can be serious. Tell your healthcare provider if you develop new or worsening swelling or puffiness, weight gain, chest pain, shortness of breath, or trouble breathing
    • Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with ZYNLONTA® but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with ZYNLONTA®. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding
    • Read full Important Safety Information
    • Infections. Serious infections, including infections that can cause death, have happened in people treated with ZYNLONTA®. Tell your healthcare provider right away if you have new or worsening signs or symptoms of infection
    • Skin reactions. Serious skin reactions have happened in people treated with ZYNLONTA®. Tell your healthcare provider if you get new or worsening skin reactions, including sensitivity to sunlight, skin rash, peeling, redness or irritation. You may burn more easily or get severe sunburns

    The most common side effects of ZYNLONTA® include:

    • feeling tired or weak
    • skin rash
    • swelling
    • nausea
    • muscle or joint pain
    • increase in blood sugar (hyperglycemia)
    • changes in certain blood or laboratory tests

    ZYNLONTA® may cause fertility problems in males which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ZYNLONTA®.

    What should I avoid while receiving ZYNLONTA®?

    Avoid or limit your exposure to sunlight, including sunlight through glass, such as buildings or vehicle windows and artificial sunlight such as sunlamps or tanning beds. Exposure to sunlight during treatment with ZYNLONTA® can cause skin reaction or rash. Use sun protection measures such as sunscreen and wear loose-fitting clothes that cover your skin while out in sunlight.

    Before you receive ZYNLONTA®, tell your healthcare provider about all of your medical conditions, including if you:

    • have an active infection or have had one recently
    • have liver problems
    • are pregnant or plan to become pregnant. ZYNLONTA® can harm your unborn baby

      Females who can become pregnant:

      • your healthcare provider may do a pregnancy test before starting treatment with ZYNLONTA®
      • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 10 months after the last dose of ZYNLONTA®. Talk to your healthcare provider about effective birth control. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZYNLONTA®

      Males with female partners who can become pregnant:

      • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 7 months after the last dose of ZYNLONTA®
    • are breastfeeding or plan to breastfeed. It is not known if ZYNLONTA® passes into breast milk. Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®

    Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine.

    You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.

    Please see the full Prescribing Information for ZYNLONTA®, including Patient Information, for additional Important Safety Information.